Using PCSK9 inhibition as a therapeutic approach for COVID-19 presents several challenges and potential limitations. As of my last knowledge update in September 2023, clinical data supporting its use were limited. This lack of data means that the clinical impact and safety of PCSK9 inhibitors for COVID-19 remain uncertain.1
References
1Arsh H, Manoj Kumar FNU, Simran FNU, et al. Role of PCSK9 inhibition during the inflammatory stage of SARS-COV-2: an updated review. Annals of Medicine and Surgery. 2024;86(2):899. doi:10.1097/MS9.0000000000001601